Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
Rosalba Torrisi, Marco Colleoni, Paolo Veronesi, Andrea Rocca, Giulia Peruzzotti, Gianluca Severi, Marta Medici, Giuseppe Renne, Mattia Intra, Alberto Luini, Franco Nolè, Giuseppe Viale, Aron Goldhirsch
Breast | Published : 2007
Patients with hormone receptor-positive tumors less often show a pathological complete response (pCR) than do those with hormone receptor-negative tumors. The addition of endocrine therapies may improve the clinical benefits of primary therapies in these patients. We investigated the efficacy of the epirubicin+cisplatin+fluorouracil (ECF) as continuous infusion) regimen in association with a gonadotropin-releasing hormone (GnRH) analog in 36 premenopausal women with T2-T4a-d N0-2 M0 ER and/or PgR-positive breast cancer. Median age was 39.5 years (range 26-53). Clinical response (complete or partial) was observed in 27 out of 36 patients (75% 95% CI 57.8-87.9%) and a pCR was observed in four ..View full abstract